Tran, M;
Neves, J;
Stamati, K;
Redondo, P;
Cope, A;
Brew-Graves, C;
Williams, N;
... Emberton, M; + view all
(2019)
Acceptability and feasibility study of patient-specific ‘tumouroids’ as personalised treatment screening tools: protocol for prospective tissue and data collection of participants with confirmed or suspected renal cell carcinoma.
International Journal of Surgery Protocols
, 14
pp. 24-29.
10.1016/j.isjp.2019.03.019.
Preview |
Text
1-s2.0-S246835741830024X-main.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Introduction: ‘Personalised medicine’ aims to tailor interventions to the individual, and has become one of the fastest growing areas of cancer research. One of these approaches is to harvest cancer cells from patients and grow them in the laboratory, which can then be subjected to treatments and the response assessed. We have developed a 3D tumour model with a complex protein matrix that mimics the tumour stroma, cell to cell and cell-matrix interactions seen in vivo, called a tumouroid. In this study, we test the acceptability and feasibility of using this model to establish patient-derived tumouroids. Methods and analysis This is a first in-human study using prospective tissue and data collection of adult participants with confirmed or suspected renal cell carcinoma. The goals of the study are to assess patient acceptability to the use of patient-derived tumour models for future treatment decisions, and to assess the feasibility of generating patient-specific renal cancer tumouroids that can be challenged with drugs. These goals will be realised through the collection of tumour samples (expected n=10), participant-completed questionnaires (expected n=10), and in-depth semi-structured interviews with patients (expected n=5). Collected multiregional tumour samples will be dissociated to isolate primary cells which are then expanded in vitro and incorporated into tumouroids. Drug challenge will ensue and the response will be categorised into “responder”, “weak responder”, and “non-responder”. Statistical analysis will be descriptive. Ethics and dissemination: The study has ethical approval (REC reference 17/LO/1744). Findings will be made available to patients, clinicians, funders, and the National Health Service (NHS) through presentations at national and international meetings, peer-reviewed publications, social media and patient support groups. Trial Registration: Registered on ClinicalTrials.gov (NCT03300102).
Archive Staff Only
 |
View Item |
